File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Relationship between HCC and serum markers in NA-treated patients with undetectable HBV DNA

TitleRelationship between HCC and serum markers in NA-treated patients with undetectable HBV DNA
Authors
Issue Date2016
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 25th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. In Hepatology International, 2016, v. 10 n. 1 suppl., p. S298, abstract no. P-0577 How to Cite?
AbstractBACKGROUND AND AIMS: Patients with undetectable HBV DNA under nucleos(t)ide analogue (NA) treatment can still develop hepatocellular carcinoma (HCC). We aimed to examine the relationship between hepatitis B surface and core-related antigens (HBsAg; HBcrAg) and HCC development. METHODS: Seventy-six HBV carriers who developed HCC with undetectable serum HBV DNA after at least one-year NA therapy were compared with 152 matched controls. Clinical and laboratory parameters were analysed. RESULTS: There were no significant differences in HBsAg or HQHBsAg levels. There was a significant difference in the median values of both pre- and post-treatment HBcrAg levels between the HCC group and controls (pre-treatment: 279.0 vs 35.4 kU/mL, respectively, P = 0.005; post-treatment: 10.2 vs 1.7 kU/mL, respectively, P = 0.005). A cutoff value of post-treatment HBcrAg level[7.8 kU/mL yielded an area under receiver operating curve (AUROC) of 0.61 with a negative predictive value (NPV) of 77.0 %. The OR of HCC development was 3.27. For the subgroup of non-cirrhotic patients, the median values of post-treatment HBcrAg level of the HCC group and controls were 10.2 and 1.0 kU/mL respectively (P = 0.001). A cutoff value of HBcrAg level[7.9 kU/mL yielded an AUROC of 0.70 with a NPV of 80.6 %. The OR of HCC development was 5.95. CONCLUSION: A higher pre- and post-treatment HBcrAg level (but not HBsAg or HQ-HBsAg) was associated with an increased risk of HCC development in patients who achieved undetectable serum HBV DNA while on NA therapy. The effects of NA on HBcrAg level for reduction of HCC development warrant further investigation.
DescriptionThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan
Poster Presentation: P-0577
Persistent Identifierhttp://hdl.handle.net/10722/234177
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorCheung, KSM-
dc.contributor.authorSeto, WKW-
dc.contributor.authorWong, DKH-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, MF-
dc.date.accessioned2016-10-14T06:59:37Z-
dc.date.available2016-10-14T06:59:37Z-
dc.date.issued2016-
dc.identifier.citationThe 25th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. In Hepatology International, 2016, v. 10 n. 1 suppl., p. S298, abstract no. P-0577-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/234177-
dc.descriptionThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan-
dc.descriptionPoster Presentation: P-0577-
dc.description.abstractBACKGROUND AND AIMS: Patients with undetectable HBV DNA under nucleos(t)ide analogue (NA) treatment can still develop hepatocellular carcinoma (HCC). We aimed to examine the relationship between hepatitis B surface and core-related antigens (HBsAg; HBcrAg) and HCC development. METHODS: Seventy-six HBV carriers who developed HCC with undetectable serum HBV DNA after at least one-year NA therapy were compared with 152 matched controls. Clinical and laboratory parameters were analysed. RESULTS: There were no significant differences in HBsAg or HQHBsAg levels. There was a significant difference in the median values of both pre- and post-treatment HBcrAg levels between the HCC group and controls (pre-treatment: 279.0 vs 35.4 kU/mL, respectively, P = 0.005; post-treatment: 10.2 vs 1.7 kU/mL, respectively, P = 0.005). A cutoff value of post-treatment HBcrAg level[7.8 kU/mL yielded an area under receiver operating curve (AUROC) of 0.61 with a negative predictive value (NPV) of 77.0 %. The OR of HCC development was 3.27. For the subgroup of non-cirrhotic patients, the median values of post-treatment HBcrAg level of the HCC group and controls were 10.2 and 1.0 kU/mL respectively (P = 0.001). A cutoff value of HBcrAg level[7.9 kU/mL yielded an AUROC of 0.70 with a NPV of 80.6 %. The OR of HCC development was 5.95. CONCLUSION: A higher pre- and post-treatment HBcrAg level (but not HBsAg or HQ-HBsAg) was associated with an increased risk of HCC development in patients who achieved undetectable serum HBV DNA while on NA therapy. The effects of NA on HBcrAg level for reduction of HCC development warrant further investigation.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.titleRelationship between HCC and serum markers in NA-treated patients with undetectable HBV DNA-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.doi10.1007/s12072-016-9707-8-
dc.identifier.hkuros267656-
dc.identifier.volume10-
dc.identifier.issue1 suppl.-
dc.identifier.spageS298, abstract no. P-0577-
dc.identifier.epageS298, abstract no. P-0577-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats